U.S. Sen. Kirsten Gillibrand (D-N.Y.) and Sen. Rick Scott (R-Fla.) announced July 23 that the Senate Health, Education, Labor and Pensions Committee approved the bipartisan CLEAR LABELS Act, legislation that would require prescription drug labels to disclose where active pharmaceutical ingredients (APIs) and finished drugs are manufactured.
The bill passed the HELP Committee by a 21-1 vote and now moves to the full Senate. According to the senators’ announcement, the legislation — Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) — is intended to give patients, pharmacists and providers information about drug origins to strengthen accountability across the supply chain.
What the bill would do
The CLEAR LABELS Act would add country-of-origin and original manufacturer disclosure requirements to the U.S. prescription drug supply chain, including for active pharmaceutical ingredients. Supporters say the measure aims to improve transparency and help identify vulnerabilities where drugs or ingredients are manufactured overseas.
Senators’ statements
Sen. Gillibrand said the measure would make information about where prescription drugs are manufactured “readily accessible to patients, pharmacists, purchasers, and providers” and that she will continue pressing for full congressional passage.
Sen. Scott described committee passage as “a massive win for consumer safety and transparency,” saying the legislation responds to concerns raised by Senate committee work about foreign sources of generics and APIs.
Next steps and context
With committee approval complete, the bill heads to the full Senate. The public text of the bill is available from the sponsoring office. The senators highlighted that many drugs and APIs are produced overseas — particularly in China and India — and that current federal labeling rules do not require disclosure of manufacturing origins.
Senate offices say the measure is intended to give regulators, providers and patients better visibility into the drug supply chain. Additional details about implementation, enforcement, or expected timelines for a floor vote were not included in the announcement.
Source: U.S. Sen. Kirsten Gillibrand press release. Full bill text: https://www.gillibrand.senate.gov/wp-content/uploads/2026/02/CLEAR-LABELS-Act.pdf
